Tag Archives: Tmunity

Gilead’s Cell Therapy Revenues Continue to Grow; Arcellx and Tmunity Deals Completed; Yescarta and Tecartus NICE Recommendations in England; Gilead’s Q1 2023 Earnings Call Summary

On Thursday, April 27, Gilead (Kite) held its Q1 2023 earnings call (press release / presentation) highlighting the increased sales for Yescarta and Tecartus and the clinical milestones of its cell therapy franchise. Additionally, on April 27, NHS England announced an expansion of access for Yescarta and Tecartus (press release), following NICE recommendations for 2L LBCL and adult B-ALL respectively. Below, Celltelligence provides insights on Gilead’s cell therapy revenue increase, while discussing the potential of recent approvals in several geographies to increase ex-US sales for Yescarta and Tecartus.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on Gilead’s Acquisition of Tmunity

On Tuesday, December 20, 2022, Gilead (Kite) announced (press release) the acquisition of Tmunity Therapeutics. As part of the transaction, Gilead will continue Tmunity’s strategic research and licensing agreement with UPenn. Below, Celltelligence provides insights on the acquisition, while discussing Gilead’s potential strategy when it comes to solid tumors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on Tmunity’s Decision to Drop TmPSMA-01: Will Companies Opt for More CAR-T Engineering or Better Drugs to Manage MAS?

Tmunity recently disclosed that the FDA enforced the termination of their TmPSMA-01 (PSMA CAR-T) Ph1 trial in prostate cancer following the death of two patients (press release). Below, Celltelligence provides insights on how Tmunity’s PSMA CAR-T compares with key competitors Poseida (P-PSMA-101) and Autolus (AUTO7), while discussing how additional engineering or pharmacological intervention could be needed to improve CAR-T safety in solid tumors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

JPM 2021 Day 3: Allogene, Autolus, and Tmunity

On the third day of JPM 2021, Celltelligence covered presentations by Allogene (presentation), Autolus (presentation), and Tmunity (presentation). Below, Celltelligence provides a topline summary of key takeaways from each company followed by more in-depth coverage below.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.